Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotech company, has scheduled its first quarter 2025 financial results announcement and business update for May 8, 2025 after market close. The company will host a conference call and webcast at 4:30 p.m. ET the same day. Investors can access the conference call via 1.877.407.0789 with Conference ID 13752361. An archived replay will be available on the company's website following the event.
Longeveron (NASDAQ: LGVN), una società biotecnologica di medicina rigenerativa in fase clinica, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 e un aggiornamento aziendale per il 8 maggio 2025 dopo la chiusura del mercato. La società terrà una conference call e una webcast alle 16:30 ET dello stesso giorno. Gli investitori potranno accedere alla conference call chiamando il numero 1.877.407.0789 con ID conferenza 13752361. Una registrazione sarà disponibile sul sito web dell'azienda dopo l'evento.
Longeveron (NASDAQ: LGVN), una empresa biotecnológica de medicina regenerativa en etapa clínica, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 y una actualización comercial para el 8 de mayo de 2025 después del cierre del mercado. La compañía realizará una llamada conferencia y una transmisión en vivo a las 4:30 p.m. ET del mismo día. Los inversores pueden acceder a la llamada conferencia marcando 1.877.407.0789 con ID de conferencia 13752361. Una repetición archivada estará disponible en el sitio web de la empresa después del evento.
Longeveron(NASDAQ: LGVN)은 임상 단계 재생 의학 바이오텍 회사로서, 2025년 1분기 재무 실적 발표 및 사업 업데이트를 2025년 5월 8일 장 마감 후에 예정하고 있습니다. 당일 오후 4시 30분(동부시간)에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다. 투자자들은 1.877.407.0789번으로 전화하여 회의 ID 13752361을 입력해 컨퍼런스 콜에 참여할 수 있습니다. 행사가 끝난 후 회사 웹사이트에서 녹화된 재방송을 시청할 수 있습니다.
Longeveron (NASDAQ : LGVN), une société biotechnologique en médecine régénérative en phase clinique, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 ainsi qu'une mise à jour commerciale pour le 8 mai 2025 après la clôture du marché. La société organisera une conférence téléphonique et une webdiffusion à 16h30 ET le même jour. Les investisseurs peuvent accéder à la conférence téléphonique en appelant le 1.877.407.0789 avec l'ID de conférence 13752361. Une rediffusion sera disponible sur le site internet de la société après l'événement.
Longeveron (NASDAQ: LGVN), ein biotechnologisches Unternehmen für regenerative Medizin in der klinischen Phase, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 und ein Geschäftsupdate für den 8. Mai 2025 nach Börsenschluss geplant. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten. Investoren können über die Nummer 1.877.407.0789 mit der Konferenz-ID 13752361 an der Telefonkonferenz teilnehmen. Eine Aufzeichnung wird nach der Veranstaltung auf der Website des Unternehmens verfügbar sein.
- None.
- None.
MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report first quarter 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.
| Conference Call and Webcast Details: | |||
| Conference Call Number: | 1.877.407.0789 | ||
| Conference ID: | 13752361 | ||
| Call meTM Feature: | Click Here | ||
| Webcast: | Click Here | ||
An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
When will Longeveron (LGVN) report Q1 2025 earnings?
What time is Longeveron's Q1 2025 earnings call?
How can I access Longeveron's Q1 2025 earnings call?
What does Longeveron (LGVN) do as a company?
